Reviva Pharmaceuticals I... (RVPH)
NASDAQ: RVPH
· Real-Time Price · USD
0.52
-0.02 (-3.70%)
At close: Aug 18, 2025, 3:59 PM
0.52
0.76%
After-hours: Aug 18, 2025, 07:59 PM EDT
-3.70% (1D)
| Bid | 0.5 |
| Market Cap | 35.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -0.81 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.55 |
| Volume | 3,463,076 |
| Avg. Volume (20D) | 2,854,171.1 |
| Open | 0.54 |
| Previous Close | 0.54 |
| Day's Range | 0.49 - 0.55 |
| 52-Week Range | 0.30 - 4.28 |
| Beta | -0.08 |
About RVPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RVPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RVPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
+15.83%
Reviva Pharmaceuticals Holdings shares are trading...
Unlock content with
Pro Subscription
1 month ago
-53.12%
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced a $10 million public offering of 20 million shares and dual warrants at a combined price of $0.50 per share and accompanying warrants.
8 months ago · seekingalpha.com
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is LowReviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announc...